Evidence map›Paper›PMID 27528230›Full record

ArticleOncotarget2016

The HERC2 ubiquitin ligase is essential for embryonic development and regulates motor coordination.

Monica Cubillos-Rojas, Taiane Schneider, Ouadah Hadjebi, Leonardo Pedrazza, Jarbas Rodrigues de Oliveira, Francina Langa, Jean-Louis Guénet, Joan Duran, Josep Maria de Anta, Soledad Alcántara and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Stem cell models of Angelman syndrome.Frontiers in cell and developmental biology · 2023
    Review
  12. Article
  13. Article
  14. Novel loss-of-function mutation inJournal of medical genetics · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Monica Cubillos-RojasDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Taiane SchneiderDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Ouadah HadjebiDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Leonardo PedrazzaDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Jarbas Rodrigues de OliveiraLaboratório de Pesquisa em Biofísica Celular e Inflamação, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Francina LangaDépartement de Biologie du Développement, Institut Pasteur, Paris, France.
Jean-Louis GuénetDépartement de Biologie du Développement, Institut Pasteur, Paris, France.
Joan DuranDepartament de Patologia i Terapèutica Experimental, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Josep Maria de AntaDepartament de Patologia i Terapèutica Experimental, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Soledad AlcántaraDepartament de Patologia i Terapèutica Experimental, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Rocio RuizDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Eva María Pérez-VillegasDepartamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, Sevilla, Spain.
Francisco J Aguilar-MontillaDepartamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, Sevilla, Spain.
Ángel M CarriónDepartamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, Sevilla, Spain.
Jose Angel ArmengolDepartamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, Sevilla, Spain.
Emma BapleInstitute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Wellcome Wolfson Centre, Exeter, UK.
Andrew H CrosbyInstitute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Wellcome Wolfson Centre, Exeter, UK.
Ramon BartronsDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Francesc VenturaDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Jose Luis RosaDepartament de Ciències Fisiològiques, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Universitat de Barcelona · ESInstitut d'Investigació Biomédica de Bellvitge · ESUniversidad Pablo de Olavide · ESInstitut Pasteur · FRPontifícia Universidade Católica do Rio Grande do Sul · BRUniversity of Exeter · GBUniversidad de Sevilla · ES

Funding

Medical Research Council G1001931
6 · The paper itself

Abstract

A mutation in the HERC2 gene has been linked to a severe neurodevelopmental disorder with similarities to the Angelman syndrome. This gene codifies a protein with ubiquitin ligase activity that regulates the activity of tumor protein p53 and is involved in important cellular processes such as DNA repair, cell cycle, cancer, and iron metabolism. Despite the critical role of HERC2 in these physiological and pathological processes, little is known about its relevance in vivo. Here, we described a mouse with targeted inactivation of the Herc2 gene. Homozygous mice were not viable. Distinct from other ubiquitin ligases that interact with p53, such as MDM2 or MDM4, p53 depletion did not rescue the lethality of homozygous mice. The HERC2 protein levels were reduced by approximately one-half in heterozygous mice. Consequently, HERC2 activities, including ubiquitin ligase and stimulation of p53 activity, were lower in heterozygous mice. A decrease in HERC2 activities was also observed in human skin fibroblasts from individuals with an Angelman-like syndrome that express an unstable mutant protein of HERC2. Behavioural analysis of heterozygous mice identified an impaired motor synchronization with normal neuromuscular function. This effect was not observed in p53 knockout mice, indicating that a mechanism independent of p53 activity is involved. Morphological analysis showed the presence of HERC2 in Purkinje cells and a specific loss of these neurons in the cerebella of heterozygous mice. In these animals, an increase of autophagosomes and lysosomes was observed. Our findings establish a crucial role of HERC2 in embryonic development and motor coordination.

Indexed as

Angelman SyndromeAnimalsCell Line, TumorCerebellumEmbryonic DevelopmentFemaleFibroblastsGuanine Nucleotide Exchange FactorsHeterozygoteHomozygoteHumansImmunohistochemistryMiceMice, Inbred C57BLMice, KnockoutMicroscopy, ElectronGuanine Nucleotide Exchange FactorsHerc2 protein, mouseTumor Suppressor Protein p53Ubiquitin-Protein LigasesAngelman syndromebehavioural analysisp53Pathology SectionPurkinje cellsubiquitin

Identifiers

PMID27528230
PMCPMC5302898
OpenAlexW2518051270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.